Swissmedic resumes Inspections
Swissmedic, the Swiss Agency for Therapeutic Products, has announced "to resume regular on-site inspections", provided that the "necessary protective measures can be complied with". A safe inspection procedure must be guaranteed for all those involved.
Before the GMP/GDP inspection, the company to be inspected must fill out a questionnaire. This questionnaire contains instructions and measures which should be observed during the inspection. The companies are asked to complete the questionnaire and to confirm the measures accordingly.
On site, the inspected company must then make appropriate arrangements, such as "meeting rooms with sufficient space, restricted number of participants, electronic resources" and wearing face masks if necessary.
Related GMP News
21.10.2024Root Cause Analysis: What can be found in FDA Warning Letters?
21.10.2024Do you want to host FDA Staff? FDA announces Experiential Learning Site Visit Program
09.10.2024Management circumvents Quality Department in Deviation Classification - FDA Warning Letter
09.10.2024Despite MRA: Why does the FDA inspect so frequently in the EU?
02.10.2024Swissmedic launched own GMDP Database
18.09.2024Large Number of Deficiencies at Indian Manufacturer leads to Warning Letter